Literature DB >> 28941082

Liver biopsy in assessment of extended criteria donors.

Joseph B Oliver1, Praveena Machineni1, Advaith Bongu1, Trusha Patel1, Joseph Nespral2, Carie Kadric2, Michael J Goldstein3, Harvey Lerner3, David Gee4, Richard Hillbom4, Lloyd Brown1, Kenneth Washburn5, Baburao Koneru1.   

Abstract

The safety and liver utilization with prerecovery liver biopsy (PLB) in extended criteria liver donors are unclear. We conducted a retrospective cohort study in 1323 brain death donors (PLB = 496) from 3 organ procurement organizations (OPOs). Outcomes were complications, preempted liver recovery (PLR), and liver transplantation (LT). Additional analyses included liver-only and propensity score-matched multiorgan donor subgroups. PLB donors were older (57 versus 53 years; P < 0.001). Hepatitis C antibody positivity (14.3% versus 9.6%, P = 0.01) and liver-only donors (42.6% versus 17.5%; P < 0.001) were more prevalent. The PLB cohort had fewer complications (31.9% versus 42.3%; P < 0.001). In the PLB cohort, PLR was significantly higher (odds ratio [OR], 3.45; 95% confidence interval [CI], 2.42-4.92) and LT lower (OR, 0.69; 95% CI, 0.52-0.91). In liver-only and propensity score-matched multiorgan donor subgroups, PLR was significantly higher (OR, 1.76; 95% CI, 1.06-2.94 and OR, 2.29; 95% CI, 1.37-3.82, respectively) without a decrease in LT (OR, 0.71; 95% CI, 0.43-1.18 and OR, 0.91; 95% CI, 0.63-1.33, respectively) in PLB subgroups. In conclusion, in extended criteria liver donors, PLB is safe and decreases futile liver recovery without decreasing LT. Increased use of PLB, especially in liver-only donors, is likely to save costs to OPOs and transplant centers and improve efficiencies in organ allocation. Liver Transplantation 24 182-191 2018 AASLD.
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 28941082     DOI: 10.1002/lt.24947

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  2 in total

1.  [Percutaneous liver biopsy before organ removal-Impact on organ allocation and costs in liver transplantation].

Authors:  Christian Beltzer; Markus Quante; Myriam Rheinberger; Hideo Andreas Baba; Fuat Saner; Falko Fend; Thomas Biet; Alfred Königsrainer; Silvio Nadalin
Journal:  Chirurg       Date:  2021-01       Impact factor: 0.955

2.  Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Helena B Thomaides-Brears; Naim Alkhouri; Daniela Allende; Mukesh Harisinghani; Mazen Noureddin; Nancy S Reau; Marika French; Carlos Pantoja; Sofia Mouchti; Donna R H Cryer
Journal:  Dig Dis Sci       Date:  2021-06-15       Impact factor: 3.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.